Skip to main content

Table 3 Ongoing clinical trials with PD-1/PD-L1 inhibitors in TETs

From: Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives

N

Interventions

Phase

Patient(n)

Sponsors

Primary endpoint

Identifier

1

Nivolumab

II

55

European Organization for Research and Treatment of Cancer—EORTC

6 m-PFS

NCT03134118

2

Atezolizumab

II

34

Hoffmann-La Roche

ORR

NCT04321330

3

Nivolumab

II

117

Vanderbilt-Ingram Cancer Center

ORR

NCT03583086

4

Avelumab

II

55

National Cancer Institute (NCI)

ORR

NCT03076554

5

Chemotherapy + 

Pembrolizumab

IV

40

Tangdu Hospital, Fourth Military Medical University

Xi'an, Shaanxi, China

ORR

NCT04554524

6

Pembrolizumab

Lenvatinib 10 mg

II

43

Medica Scientia Innovation Research

5 m-PFS

NCT04710628

7

Toripalimab

Chemotherapy

II

15

Shanghai Pulmonary Hospital, Shanghai, China

MPRR

NCT04667793

8

Pembrolizumab

Radiation

II

40

Samsung Medical Center

MPRR

NCT03858582

9

KN046 (PD-L1& CTLA-4 inhibitor)

II

29

Weill Medical College of Cornell University

ORR

NCT04925947

10

KN046 (PD-L1& CTLA-4 inhibitor)

II

66

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

ORR

NCT04469725

11

M7824 (PD-L1& TGF-ß inhibitor)

II

38

National Cancer Institute (NCI)

ORR

NCT04417660

12

SO-C101 (IL-15 activator) + Pembrolizumab

I

200

SOTIO Biotech AG

DLT

NCT04234113

13

XmAb20717 (PD-1 & CTLA-4 inhibitor)

I

154

Xencor, Inc

TRAE

NCT03517488

14

Pembrolizumab

Sunitinib Malate (RTK inhibitor)

II

40

Ohio State University Comprehensive Cancer Center

ORR

NCT03463460

  1. PFS Progression-free survival, ORR Objective response rate, MPRR Major pathologic response rate, DLT Dose-Limiting Toxicities, TRAE Treatment-related adverse events